The most common tirzepatide side effects are gastrointestinal
The overwhelming majority of tirzepatide side effects involve the gut. In the pooled Zepbound weight-management trials (Study 1 / SURMOUNT-1 and Study 2), gastrointestinal reactions occurred in about 56% of patients at every dose (5 mg, 10 mg, and 15 mg) versus 30% on placebo (Zepbound Prescribing Information, 2026). The four that stand out are nausea, diarrhea, vomiting, and constipation.
These reactions stem from how the drug works. Tirzepatide slows how quickly the stomach empties, which prolongs fullness and reduces appetite but also produces nausea in susceptible people. The stomach adapts over weeks, which is why the label notes that most nausea, vomiting, and diarrhea occurred during dose escalation and then decreased over time.
One useful nuance: placebo rates are not zero. Because 8% of placebo patients also reported nausea, the nausea genuinely attributable to the drug is closer to 17-21 percentage points, not the raw 25-29%. Constipation is the one reaction that runs higher at lower doses (17% at 5 mg down to 11% at 15 mg), likely reflecting how long patients have been on therapy rather than the dose itself.
How side effect rates change with dose
The table above shows the FDA-reported frequency of each common reaction at 5 mg, 10 mg, and 15 mg from the pooled Zepbound trials (2,519 tirzepatide patients vs. 958 on placebo). A few patterns are worth understanding, though none of this tells you what dose is right for you — that is a prescriber's decision.
Vomiting and diarrhea climb steadily with dose, while nausea barely moves past the first therapeutic dose (25% at 5 mg to 29% at 10 mg). Constipation runs the opposite direction. This is why clinicians escalate the dose slowly, in roughly 4-week steps, and why side effects tend to flare briefly after each increase before settling.
- Clearly dose-dependent: vomiting (8% to 13%), diarrhea (19% to 23%), hypotension (1% to 2%).
- Roughly dose-stable after 5 mg: nausea, abdominal pain, indigestion, injection-site reactions, burping.
- Inversely related to dose: constipation (17% to 11%).
- Not strongly tied to dose: hair loss, fatigue, hypersensitivity reactions, acid reflux.
Why side effects peak during titration
Tirzepatide is started low and increased in steps precisely to reduce gastrointestinal side effects. The FDA label is explicit: the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time (Mounjaro and Zepbound Prescribing Information).
Each dose increase can trigger a fresh, usually temporary, wave of nausea or looser stools as the gut re-adapts. Once a person reaches a stable maintenance dose and stays on it for several weeks, tolerability typically improves substantially. Discontinuation because of gastrointestinal side effects was uncommon but rose with dose — 1.9% at 5 mg, 3.3% at 10 mg, and 4.3% at 15 mg, versus 0.5% on placebo.
Important: the dose and the pace of increases are set and adjusted by a prescriber for each individual. Do not increase, decrease, skip, or double a dose on your own to manage side effects — talk to your clinician, who may slow the schedule or pause an increase.
Serious and rare risks the label flags
Beyond routine gut symptoms, the tirzepatide labels list several uncommon but serious risks. These are reasons a prescriber screens patients before starting and monitors them afterward.
Acute pancreatitis — including fatal and non-fatal hemorrhagic or necrotizing forms — has been reported. Warning signs include persistent, severe abdominal pain, sometimes radiating to the back, with or without vomiting. The label directs clinicians to discontinue if pancreatitis is suspected.
Acute gallbladder disease (gallstones, inflammation, or gallbladder removal) was reported in about 1.1% (cholelithiasis) and 0.7% (cholecystitis) of Zepbound patients versus 1% and 0.2% on placebo; in Mounjaro diabetes trials, acute gallbladder disease was reported by 0.6% of patients vs. 0% on placebo. Rapid weight loss itself raises gallstone risk.
- Acute kidney injury: reported in 0.5% of Zepbound patients vs. 0.2% on placebo — usually a consequence of dehydration from severe nausea, vomiting, or diarrhea.
- Serious hypersensitivity: anaphylaxis and angioedema have been reported after marketing; seek emergency care for swelling of the face or throat, widespread hives, or trouble breathing.
- Hypoglycemia: mainly when combined with insulin or a sulfonylurea; a prescriber may lower those medications.
- Diabetic retinopathy: patients with a history of it should be monitored for progression.
- Suicidal thoughts or behavior: the Zepbound label directs monitoring for new or worsening depression or suicidal ideation.
- Pulmonary aspiration: because the drug slows stomach emptying, tell any surgeon or anesthesiologist you take it before a procedure.
The thyroid C-cell tumor boxed warning
Both Mounjaro and Zepbound carry the FDA's most serious warning — a boxed warning — for thyroid C-cell tumors. In two-year studies, tirzepatide caused dose-dependent thyroid C-cell tumors (adenomas and carcinomas) in male and female rats at clinically relevant exposures.
It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans; the human relevance of the rat findings has not been determined. Because of this uncertainty, tirzepatide is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The label tells patients to report symptoms of a thyroid tumor — a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness. Routine calcitonin blood tests or thyroid ultrasound screening are described as being of uncertain value for early detection.
Birth control: a specific interaction to know
Tirzepatide can reduce the effectiveness of oral hormonal contraceptives (birth control pills). Because the drug delays stomach emptying — an effect that is largest after the first dose and after each increase — the label advises patients using oral contraceptives to switch to a non-oral method or add a barrier method (such as condoms) for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.
Hormonal contraceptives that are not taken by mouth — such as an implant, IUD, patch, ring, or injection — are not expected to be affected. Tirzepatide may also cause fetal harm; the label directs stopping it once pregnancy is recognized. Anyone who could become pregnant should discuss contraception with their prescriber before starting.
Red flags: when to seek medical care
Most tirzepatide side effects are mild and improve with time, but some symptoms need prompt professional evaluation rather than waiting it out or self-adjusting the dose. Contact a clinician or seek urgent care for any of the following, based on the FDA labels' warnings.
This is not an exhaustive list, and it is not a substitute for individual medical advice. When in doubt, call your prescriber or, for emergencies, your local emergency number.
- Severe or persistent abdominal pain, especially pain that radiates to the back (possible pancreatitis).
- Pain in the upper right belly, fever, or yellowing of the skin or eyes (possible gallbladder problem).
- Signs of a serious allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives.
- Relentless vomiting or diarrhea, little urine, dizziness, or fainting (dehydration and possible kidney injury).
- New or worsening depression, mood changes, or thoughts of self-harm.
- A lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.
Compounded tirzepatide is not FDA-approved
Some telehealth providers advertise compounded tirzepatide. Compounded versions are prepared by pharmacies and are not FDA-approved finished drugs — they have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality, and their contents, purity, and dosing can differ from the branded Mounjaro and Zepbound products this page describes.
Because compounded formulations are not standardized, the frequency data on this page — drawn from the FDA-approved Mounjaro and Zepbound labels — may not accurately describe a compounded product. Discuss any compounded option with a licensed prescriber and pharmacist before using it.
Easing common GI side effects (comfort measures)
Most tirzepatide GI side effects are mild to moderate and ease as the body adjusts over the first weeks. The strategies below are general comfort measures many people discuss with their clinician — they are not medical advice, and they never replace the dose and timing decisions a prescriber makes.
If nausea, vomiting, or diarrhea is severe or persistent, or comes with signs of dehydration or the red-flag symptoms above, contact a clinician or seek urgent care rather than self-managing.
- Smaller, more frequent meals — and stopping at the first feeling of fullness — help many people
- Bland, lower-fat foods tend to be easier; greasy, fried, very sweet, or spicy meals can worsen nausea while adjusting
- Eating slowly and staying upright for a while after meals can reduce reflux and nausea
- Sipping fluids through the day supports hydration, which matters most with vomiting or diarrhea
- Ginger (tea or candied) settles some stomachs and has no known GLP-1 interaction
- Adding fiber gradually and staying active can ease constipation